Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
An angiotensin IV analog peptide developed at Washington State University that has shown extraordinary cognitive-enhancing properties in animal models. In preclinical studies, dihexa was reported to be up to 10 million times more potent than BDNF at promoting new synapse formation, making it one of the most discussed nootropic peptides in the biohacking community.
A mixture of low-molecular-weight neuropeptides and amino acids derived from purified pig brain proteins. Approved as a drug in over 50 countries (including much of Europe and Asia) for stroke, traumatic brain injury, and Alzheimer's disease. One of the most clinically studied neuropeptide preparations in the world.
Binds to hepatocyte growth factor (HGF) receptor (c-Met), potentiating HGF/c-Met signaling which promotes synaptogenesis, dendritic spine formation, and neuronal connectivity. This mechanism is distinct from traditional nootropics and operates through growth factor pathways rather than neurotransmitter modulation.
Acts as a neurotrophic factor, mimicking the effects of BDNF, NGF, and other endogenous growth factors. Promotes neuronal survival, synaptic plasticity, and neurogenesis. Reduces excitotoxicity and oxidative stress in neural tissue. Crosses the blood-brain barrier due to its small molecular weight.
- Cognitive enhancement (investigational)
- Memory and learning support
- Neuroprotection research
- Alzheimer's disease research
- Stroke recovery and rehabilitation
- Traumatic brain injury recovery
- Alzheimer's disease (approved in some countries)
- Cognitive enhancement
- Neuroprotection
- No human clinical trials — safety profile unknown
- Theoretical cancer risk (HGF/c-Met pathway involved in tumor growth)
- Long-term effects completely unstudied in humans
- Quality control concerns with research chemical sourcing
- Derived from porcine brain — religious/ethical considerations for some
- Injection site reactions
- Rare allergic reactions
- Seizure risk at high doses (rare)
- Not FDA-approved — quality of gray-market sources varies significantly
No FDA status. Purely a research compound with preclinical data only. No IND application or clinical trials registered. Available only as a research chemical. The HGF/c-Met mechanism raises theoretical oncology concerns that would need to be addressed before clinical development.
Not FDA-approved in the United States. Approved as a prescription drug in 50+ countries including Germany, Austria, Russia, China, and most of Eastern Europe and Asia. Available in the US only as a research chemical or through international sources. Has the most robust clinical evidence base of any compound in the nootropic peptide category.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.